98902-39-7

Basic information

• Product Name: N-{3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]-propyl}-N-methyl-benzamide
• Synonyms: N-{3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]-propyl}-N-methyl-benzamide
• CAS NO: 98902-39-7
• Molecular Weight: 409.488
• Mol File: 98902-39-7.mol

Chemical Properties

• CAS DataBase Reference: N-{3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]-propyl}-N-methyl-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]-propyl}-N-methyl-benzamide(98902-39-7)
• EPA Substance Registry System: N-{3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]-propyl}-N-methyl-benzamide(98902-39-7)

Safety Data

• Hazardous Substances Data: 98902-39-7(Hazardous Substances Data)

Upstream product

• 98-88-4 benzoyl chloride 
• 65189-25-5 N¹,N²-dimethyl-N¹-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,3-propanediamine hydrochloride 
• 65189-24-4 N¹,N²-dimethyl-N²-(phenylmethyl)-N¹-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1,3-propanediamine 
• 60630-68-4 N¹,N²-dimethyl-N¹-(phenylmethyl)-1,3-propanediamine 

Relevant articles and documents

Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives

A series of N2-[(acylamino)alkyl]-6,7-dimethoxy-2,4-quinazolinediamines was synthesized as potential α1-adrenoceptor antagonists. When administered to spontaneously hypertensive rats at 10 mg/kg po, a number of propanediamine derivatives showed good antihypertensive activity, whereas the ethanediamine derivatives, albeit being structurally more closely related to prazosin, were devoid of this property. The most active derivative, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro- 2-furancarboxamide hydrochloride, alfuzosin, showed high selectivity for peripheral α1-postjunctional adrenoceptors. At equiactive antihypertensive doses, its effect on the pressor response to postural changes in conscious dog was less marked than that shown by prazosin. In the light of these results, alfuzosin was selected for clinical evaluation.